Lentiviral vector mediated siRNA knock-down of hTERT results in diminished capacity in invasiveness and in vivo growth of human glioma cells in a telomere length-independent manner

International Journal of Oncology

Volumn 31, Issue 2, 2007, Pages 361-368

  Zhao, Peng ^a   Wang, Cunzu ^a   Fu, Zhen ^a   You, Yongping ^a   Cheng, Yunxiang ^a   Lu, Xiaoming ^a   Lu, Ailin ^a   Liu, Ning ^a   Pu, Peiyu ^b   Kang, Chunsheng ^b   Salford, Leif G ^c   Fan, Xiaolong ^c  

^a NANJING MEDICAL UNIVERSITY   (China)

^b TIANJIN MEDICAL UNIVERSITY   (China)

^c LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Gene therapy; Glioma; hTERT; siRNA; Telomerase activity

Indexed keywords

ANTINEOPLASTIC AGENT; SMALL INTERFERING RNA; TELOMERASE;

ANIMAL; ARTICLE; BAGG ALBINO MOUSE; BRAIN TUMOR; CANCER INVASION; CANCER TRANSPLANTATION; GENETICS; GLIOMA; HUMAN; LENTIVIRINAE; METABOLISM; MOLECULAR GENETICS; MOUSE; NUCLEOTIDE SEQUENCE; PATHOLOGY; TELOMERE; TUMOR CELL LINE; ULTRASTRUCTURE;

ANIMALS; ANTINEOPLASTIC AGENTS; BASE SEQUENCE; BRAIN NEOPLASMS; CELL LINE, TUMOR; GLIOMA; HUMANS; LENTIVIRUS; MICE; MICE, INBRED BALB C; MOLECULAR SEQUENCE DATA; NEOPLASM INVASIVENESS; NEOPLASM TRANSPLANTATION; RNA, SMALL INTERFERING; TELOMERASE; TELOMERE;

EID: 35148876642     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.31.2.361     Document Type: Article

References (35)

1. De Angelis LM: Brain tumors. N Engl J Med 344: 114-123, 2001.
2. Schwartzbaum JA, Fisher JL, Aldape KD and Wrensch M: Epidemiology and molecular pathology of glioma. Nat Clin Pract Neurol 2: 494-503, 2006.
3. Cerni C: Telomeres, telomerase, and myc. An update. Mutat Res 462: 31-47, 2000.
4. Harada K, Arita K, Kurisu K and Tahara H: Telomerase activity and the expression of telomerase components in pituitary adenoma with malignant transformation. Surg Neurol 53: 267-274, 2000. (Pubitemid 30201533)
5. You Y, Pu P, Peng Q, Xia Z, Huang Q, Wang C and Wang G: Telomerase activity and regulation in human neuroepithelial tumors. Chin J Surg 40: 90-93, 2002.
6. Komata T, Kondo Y, Kanzawa T, et al: Treatment of malignant glioma cells with the transfer of constitutively active caspase-6 using the human telomerase catalytic subunit (human telomerase reverse transcriptase) gene promoter. Cancer Res 61: 5796-5802, 2001.
7. You Y, Pu P, Huang Q, et al: Antisense telomerase RNA inhibits the growth of human glioma cells in vitro and in vivo. Int J Oncol 28: 1225-1232, 2006.
8. Meyerson M, Counter CM, Eaton EN, et al: hEST2, the putative human telomerase catalytic subunit gene, is up-regulated in tumor cells and during immortalization. Cell 90: 785-795, 1997.
9. Tchirkov A, Rolhion C, Kemeny JL, et al: Clinical implications of quantitative real-time RT-PCR analysis of hTERT gene expression in human gliomas. Br J Cancer 88: 516-520, 2003.
10. Boldrini L, Pistolesi S, Gisfredi S, et al: Telomerase activity and hTERT mRNA expression in glial tumors. Int J Oncol 28: 1555-1560, 2006.
11. Wiznerowicz M and Trono D: Conditional suppression of cellular genes: lentivirus vector-mediated drug-inducible RNA interference. J Virol 77: 8957-8961, 2003. (Pubitemid 36936105)
12. Steffens S, Tebbets J, Kramm CM, Lindemann D, Flake A and Sena-Esteves M: Transduction of human glial and neuronal tumor cells with different lentivirus vector pseudotypes. J Neurooncol 70: 281-288, 2004. (Pubitemid 40057956)
13. Kanzawa T, Germano IM, Kondo Y, Ito H, Kyo S and Kondo S: Inhibition of telomerase activity in malignant glioma cells correlates with their sensitivity to temozolomide. Br J Cancer 89: 922-929, 2003.
14. Kim NW and Wu F: Advances in quantification and characterization of telomerase activity by the telomeric repeat amplification protocol (TRAP). Nucleic Acids Res 25: 2595-2597, 1997. (Pubitemid 27298154)
15. Hahnfeldt P, Panigrahy D, Folkman J and Hlatky L: Tumor development under angiogenic signaling: a dynamical theory of tumor growth, treatment response, and postvascular dormancy. Cancer Res 59: 4770-4775, 1997. (Pubitemid 29472873)
16. Martens UM, Brass V, Engelhardt M, et al: Measurement of telomere length in haematopoietic cells using in situ hybridization techniques. Biochem Soc Trans 28: 245-250, 2000.
17. Trono D: Lentiviral vectors: turning a deadly foe into a therapeutic agent. Gene Ther 7: 20-23, 2000.
18. Shay JW and Wright WE: Telomerase: a target for cancer therapeutics. Cancer Cell 2: 257-265, 2002.
19. Sano T, Asai A, Mishima K, Fujimaki T and Kirino T: Telomerase activity in 144 brain tumours. Br J Cancer 77: 1633-1637, 1998. (Pubitemid 28230464)
20. Le S, Zhu JJ, Anthony DC, Greider CW and Black PM: Telomerase activity in human gliomas. Neurosurgery 42: 1120-1124, 1998.
21. Sugita Y, Nakashima A, Kato S, Sakata K, Morimatsu M and Shigemori M: Telomerase activity in gliomas with the use of non-radioisotopic and semi-quantitative procedure for terminal repeat amplification protocol. Oncol Rep 7: 1087-1092, 2000.
22. Hiyama E, Yokoyama T, Tatsumoto N, et al: Telomerase activity in gastric cancer. Cancer Res 55: 3258-3262, 1995.
23. Clark GM, Osborne CK, Levitt D, Wu F and Kim NW: Telomerase activity and survival of patients with node-positive breast cancer. J Natl Cancer Inst 89: 1874-1881, 1997.
24. Taga S, Osaki T, Ohgami A, Imoto H and Yasumoto K: Prognostic impact of telomerase activity in non-small cell lung cancers. Ann Surg 230: 715-720, 1999. (Pubitemid 30191835)
25. Kraemer K, Fuessel S, Schmidt U, Kotzsch M, Schwenzer B, Wirth MP and Meye A: Antisense-mediated hTERT inhibition specifically reduces the growth of human bladder cancer cells. Clin Cancer Res 9: 3794-3800, 2003.
26. Zhang PH, Zou L and Tu ZG: RNAi-hTERT inhibition hepatocellular carcinoma cell proliferation via decreasing telomerase activity. J Surg Res 131: 143-149, 2006. (Pubitemid 43227598)
27. Pallini R, Sorrentino A, Pierconti F, et al: Telomerase inhibition by stable RNA interference impairs tumor growth and angiogenesis in glioblastoma xenografts. Int J Cancer 118: 2158-2167, 2006.
28. Falchetti ML, Fiorenzo P, Mongiardi MP, et al: Telomerase inhibition impairs tumor growth in glioblastoma xenografts. Neurol Res 28: 532-537, 2006.
29. Zhang Z, Yang X, Zhang Y, et al: Delivery of telomerase reverse transcriptase small interfering RNA in complex with positively charged single-walled carbon nanotubes suppresses tumor growth. Clin Cancer Res 12: 4933-4939, 2006.
30. Lin RX, Tuo CW, Lu QJ, Zhang W and Wang SQ: Inhibition of tumor growth and metastasis with antisense oligonucleotides (Cantide) targeting hTERT in an in situ human hepatocellular carcinoma model. Acta Pharmacol Sin 26: 762-768, 2005.
31. Kurvinen K, Syrjanen S and Johansson B: Long-term suppression of telomerase expression in HeLa cell clones, transfected with an expression vector carrying siRNA targeting hTERT mRNA. Int J Oncol 29: 279-288, 2006.
32. Hemann MT, Fridman JS, Zilfou JT, et al: An epi-allelic series of p53 hypomorphs created by stable RNAi produces distinct tumor phenotypes in vivo. Nat Genet 33: 396-400, 2003.
33. Stewart SA, Hahn WC, O'Connor BF, et al: Telomerase contributes to tumorigenesis by a telomere length-independent mechanism. Proc Natl Acad Sci USA 99: 12606-12611, 2002.
34. Li S, Rosenberg JE, Donjacour AA, Botchkina IL, Hom YK, Cunha GR and Blackburn EH: Inhibition of cancer cell growth induced by lentiviral delivery and expression of mutant-template telomerase RNA and anti-telomerase short-interfering RNA. Cancer Res 64: 4833-4840, 2004.
35. Li S, Crothers J, Haqq CM and Blackburn EH: Cellular and gene expression responses involved in the rapid growth inhibition of human cancer cells by RNA interference-mediated depletion of telomerase RNA. J Biol Chem 280: 23709-23717, 2005. (Pubitemid 40884853)